PUBLIC COMPANY
saveASTRAZENECA
USupdated 2mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
- phase2Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- phase1A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
- —A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA
- phase2A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
- phase3A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
- phase1Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
- phase2AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
🐶 Hiring Signal
News
- Biogen’s big lupus bet gets boost from new durability data for skin diseaseAll signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin within one year in patients with cutaneous lupus in a mid-stage study.…biospace · 8h ago
- How AI is transforming biopharma manufacturing facilities of the futureAs AI accelerates drug discovery, here are the ways pharmaceutical manufacturing facilities are adapting.biopharma_dive · 12h ago
- Opinion: FDA must ensure American patients can access new and experimental drugsThe FDA has taken important steps through Operation TrialBlazer and stronger scrutiny of foreign clinical data, but more must be done to make the United States more competitive in attracting clinic…biospace · 17h ago
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 3d ago
- Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestonePlus news about Regeneron. Summit Therapeutics to test cancer drug with Datroway: The biotech agreed to partner with AstraZeneca and Daiichi Sankyo on a clinical trial collaboration, testing its Tr…endpoints · 3d ago
- Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOEric Cantor, who represented Virginia in the U.S. House of Representatives for 14 years and served as House majority leader from 2011 to 2014, will step up as PhRMA’s next president and CEO on Nov.…fiercebiotech · 4d ago
- Pfizer’s eczema drug clears skin in mid-stage trialDetailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.biopharma_dive · 4d ago
- BMS reports liver injury events in lung disease program, with key readout nearBristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…biospace · 4d ago
- STAT+: HHS announces new efforts to speed up, expand clinical trials with AIFederal health officials want to speed up clinical research to compete with countries like China.stat · 5d ago
- $40M in tax incentives expected to generate 1,600+ life sciences jobs in MassachusettsOf the 38 companies receiving incentives, 31 will expand outside of Boston and Cambridge. Still, Boston and Cambridge are each expected to gain over 200 jobs. Tax incentive award recipients include…biospace · 5d ago
comments(0)
5-min edit window · permanent after that